Sanofi(SNY)Earnings, Financials & Key Ratios
SNY•NASDAQ
$43.36
$104.72B mkt cap·18.2× P/E·Price updated May 6, 2026
AboutSanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.Show more
- Revenue$46.72B+5.5%
- EBITDA$9.55B-11.8%
- Net Income$7.81B+40.5%
- EPS (Diluted)2.03-7.3%
- Gross Margin72.34%+3.1%
- EBITDA Margin20.45%-16.4%
- Operating Margin13.58%-17.1%
- Net Margin16.72%+33.2%
- ROE10.45%+43.0%
- ROIC5.46%-13.3%
- Debt/Equity0.30+32.1%
- Interest Coverage17.51+46.4%
SNY Key Insights
Sanofi (SNY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 19.0% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 5.1%
- ✓Share count reduced 2.5% through buybacks
- ✓Healthy 5Y average net margin of 15.8%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SNY Price & Volume
Sanofi (SNY) stock price & volume — 10-year historical chart
Loading chart...
SNY Growth Metrics
Sanofi (SNY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.97%
5 Years4.57%
3 Years4.82%
TTM14.11%
Profit CAGR
10 Years6.19%
5 Years-8.67%
3 Years-2.27%
TTM256.76%
EPS CAGR
10 Years2.16%
5 Years-16.19%
3 Years-13.9%
TTM96.15%
Return on Capital
10 Years7.64%
5 Years7.71%
3 Years6.7%
Last Year6.28%
SNY Recent Earnings
Sanofi (SNY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (75%)
Q2 2026Latest
Apr 23, 2026EPS
$1.10
Est $1.06
+3.8%
Revenue
$12.9B
Est $12.7B
+1.9%
Q1 2026
Jan 29, 2026EPS
$0.89
Est $0.84
+6.0%
Revenue
$14.3B
Est $11.7B
+22.4%
Q4 2025
Oct 24, 2025EPS
$1.70
Est $1.60
+6.3%
Revenue
$15.4B
Est $11.1B
+38.9%
Q3 2025
Jul 31, 2025EPS
$0.90
Est $0.96
-6.3%
Revenue
$12.6B
Est $12.4B
+2.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 23, 2026 | $1.10vs $1.06+3.8% | $12.9Bvs $12.7B+1.9% |
| Q1 2026 | Jan 29, 2026 | $0.89vs $0.84+6.0% | $14.3Bvs $11.7B+22.4% |
| Q4 2025 | Oct 24, 2025 | $1.70vs $1.60+6.3% | $15.4Bvs $11.1B+38.9% |
| Q3 2025 | Jul 31, 2025 | $0.90vs $0.96-6.3% | $12.6Bvs $12.4B+2.3% |
Based on last 12 quarters of dataView full earnings history →
SNY Peer Comparison
Sanofi (SNY) competitors in Vaccines and plasma-derived therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVO | 151.36B | 44.89 | 12.41 | 2.34% | 33.14% | 50.76% | 5.88% | 0.67 |
 AZN | 280.97B | 181.24 | 27.71 | 8.63% | 17.19% | 22.24% | 4.19% | 0.61 |
 NVS | 277.63B | 145.50 | 20.24 | 5.97% | 24.14% | 31.42% | 6.37% | 0.80 |
 GSK | 101.32B | 50.38 | 6.67 | 4.11% | 19.19% | 31.48% | 7.81% | 1.11 |
 PFE | 150.4B | 26.44 | 19.44 | -1.65% | 11.83% | 8.34% | 6.03% | 0.78 |
 MRK | 279.49B | 113.16 | 15.54 | 1.18% | 28.12% | 36.14% | 4.42% | 0.96 |
 LLY | 933.66B | 988.19 | 43.06 | 44.7% | 34.98% | 101.17% | 0.96% | 1.60 |
 ABBV | 364.63B | 206.15 | 86.98 | 8.57% | 6.91% | 62.15% | 4.89% |
Compare SNY vs Peers
Sanofi (SNY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SNY Income Statement
Sanofi (SNY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 36.22B | 35.68B | 37.63B | 37.37B | 39.17B | 40.56B | 41.62B | 44.29B | 46.72B |
| Revenue Growth % | 4.4% | -1.5% | 5.48% | -0.7% | 4.83% | 3.54% | 2.61% | 6.41% | 5.49% |
| Cost of Goods Sold | 11.61B | 11.44B | 11.98B | 12.16B | 12.26B | 11.88B | 12.63B | 13.21B | 12.92B |
| COGS % of Revenue | 32.06% | 32.05% | 31.83% | 32.54% | 31.28% | 29.29% | 30.34% | 29.82% | 27.66% |
| Gross Profit | 24.61B▲ 0% | 24.24B▼ 1.5% | 25.65B▲ 5.8% | 25.21B▼ 1.7% | 26.92B▲ 6.8% | 28.68B▲ 6.5% | 28.99B▲ 1.1% | 31.08B▲ 7.2% | 33.79B▲ 8.7% |
| Gross Margin % | 67.94% | 67.95% | 68.17% | 67.46% | 68.72% | 70.71% | 69.66% | 70.18% | 72.34% |
| Gross Profit Growth % | 2.55% | -1.49% | 5.82% | -1.72% | 6.78% | 6.53% | 1.08% | 7.21% | 8.73% |
| Operating Expenses | 18.8B | 19.57B | 22.6B | 11.1B | 18.79B | 18.52B | 22.03B | 23.83B | 27.45B |
| OpEx % of Revenue | 51.91% | 54.84% | 60.06% | 29.7% | 47.97% | 45.65% | 52.93% | 53.81% | 58.76% |
| Selling, General & Admin | 10.07B | 9.86B | 9.88B | 9.39B | 9.55B | 8.74B | 8.93B | 9.18B | 9.54B |
| SG&A % of Revenue | 27.81% | 27.63% | 26.27% | 25.13% | 24.39% | 21.55% | 21.46% | 20.74% | 20.43% |
| Research & Development | 5.47B | 5.89B | 6.02B | 5.53B | 5.69B | 6.5B | 6.51B | 7.39B | 7.84B |
| R&D % of Revenue | 15.11% | 16.52% | 16% | 14.8% | 14.53% | 16.03% | 15.64% | 16.7% | 16.79% |
| Other Operating Expenses | 3.26B | 3.81B | 6.7B | -3.82B | 3.55B | 3.28B | 6.59B | 7.25B | 10.06B |
| Operating Income | 5.8B▲ 0% | 4.68B▼ 19.4% | 3.05B▼ 34.8% | 14.11B▲ 362.6% | 8.13B▼ 42.4% | 10.16B▲ 25.1% | 6.96B▼ 31.5% | 7.25B▲ 4.2% | 6.34B▼ 12.5% |
| Operating Margin % | 16.02% | 13.11% | 8.11% | 37.77% | 20.74% | 25.05% | 16.72% | 16.38% | 13.58% |
| Operating Income Growth % | -11.13% | -19.43% | -34.75% | 362.57% | -42.42% | 25.06% | -31.51% | 4.2% | -12.52% |
| EBITDA | 9.49B | 8.96B | 10.5B | 17.78B | 11.48B | 13.27B | 11.39B | 10.84B | 9.55B |
| EBITDA Margin % | 26.2% | 25.1% | 27.89% | 47.59% | 29.3% | 32.72% | 27.37% | 24.47% | 20.45% |
| EBITDA Growth % | -3.48% | -5.64% | 17.21% | 69.44% | -35.46% | 15.62% | -14.17% | -4.84% | -11.85% |
| D&A (Non-Cash Add-back) | 3.69B | 4.28B | 7.45B | 3.67B | 3.35B | 3.11B | 4.43B | 3.59B | 3.21B |
| EBIT | 5.95B | 4.9B | 3.22B | 14.21B | 8.19B | 10.4B | 6.96B | 7.45B | 9.47B |
| Net Interest Income | -279.47M | -412.12M | -446.57M | -396.41M | -374.24M | -215.84M | 17.68M | -165.04M | -162.33M |
| Interest Income | 53.97M | 74.37M | 89.71M | 34.43M | 3.13M | 168.96M | 530.5M | 457.53M | 378.45M |
| Interest Expense | 333.43M | 486.48M | 536.27M | 430.84M | 377.37M | 384.8M | 512.82M | 622.58M | 540.78M |
| Other Income/Expense | -188M | 228M | -44M | 24M | -289M | -170M | -845M | -494M | -324M |
| Pretax Income | 5.62B▲ 0% | 4.9B▼ 12.7% | 3.01B▼ 38.7% | 14.14B▲ 370.1% | 7.84B▼ 44.6% | 9.99B▲ 27.5% | 6.12B▼ 38.8% | 6.76B▲ 10.5% | 6.02B▼ 10.9% |
| Pretax Margin % | 15.5% | 13.75% | 7.99% | 37.83% | 20.01% | 24.63% | 14.69% | 15.26% | 12.89% |
| Income Tax | 1.72B | 481M | 121M | 1.81B | 1.56B | 1.91B | 1.02B | 1.2B | 1.04B |
| Effective Tax Rate % | 30.66% | 9.81% | 4.02% | 12.78% | 19.88% | 19.11% | 16.63% | 17.82% | 17.33% |
| Net Income | 8.42B▲ 0% | 4.31B▼ 48.8% | 2.75B▼ 36.0% | 12.29B▲ 346.4% | 6.22B▼ 49.4% | 8.37B▲ 34.5% | 5.4B▼ 35.5% | 5.56B▲ 3.0% | 7.81B▲ 40.5% |
| Net Margin % | 23.24% | 12.07% | 7.32% | 32.9% | 15.89% | 20.64% | 12.98% | 12.55% | 16.72% |
| Net Income Growth % | 78.72% | -48.84% | -36.04% | 346.41% | -49.38% | 34.52% | -35.49% | 2.96% | 40.52% |
| Net Income (Continuing) | 3.89B | 4.42B | 2.89B | 12.33B | 6.28B | 8.08B | 5.1B | 5.55B | 4.98B |
| Discontinued Operations | 4.64B | -13M | -101M | 0 | 0 | 401M | 338M | 64M | 2.87B |
| Minority Interest | 169M | 159M | 174M | 146M | 350M | 368M | 313M | 350M | 334M |
| EPS (Diluted) | 3.36▲ 0% | 1.73▼ 48.5% | 1.14▼ 34.1% | 4.91▲ 330.7% | 2.49▼ 49.3% | 3.18▲ 27.7% | 2.15▼ 32.4% | 2.19▲ 1.9% | 2.03▼ 7.3% |
| EPS Growth % | 83.61% | -48.51% | -34.1% | 330.7% | -49.29% | 27.71% | -32.39% | 1.86% | -7.31% |
| EPS (Basic) | 1.50 | 1.73 | 1.14 | 4.91 | 2.49 | 3.19 | 2.15 | 2.19 | 2.03 |
| Diluted Shares Outstanding | 2.51B | 2.49B | 2.5B | 2.51B | 2.5B | 2.5B | 2.51B | 2.5B | 2.44B |
| Basic Shares Outstanding | 2.51B | 2.49B | 2.5B | 2.51B | 2.5B | 2.5B | 2.5B | 2.5B | 2.44B |
| Dividend Payout Ratio | 44.08% | 87.62% | 139.22% | 32.02% | 64.41% | 49.79% | 82.48% | 84.6% | 58.67% |
SNY Balance Sheet
Sanofi (SNY) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 26.35B | 24.58B | 28.61B | 33.7B | 30.56B | 34.03B | 30.66B | 42.59B | 30.95B |
| Cash & Short-Term Investments | 10.31B | 6.92B | 9.74B | 13.91B | 10.1B | 12.74B | 8.71B | 7.93B | 7.66B |
| Cash Only | 10.31B | 6.92B | 9.74B | 13.91B | 10.1B | 12.74B | 8.71B | 7.44B | 7.66B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 486M | 0 |
| Accounts Receivable | 8.68B | 9.35B | 10.08B | 9.95B | 9.79B | 10.75B | 11.04B | 10.63B | 396.83M |
| Days Sales Outstanding | 87.42 | 95.61 | 97.8 | 97.22 | 91.19 | 96.7 | 96.82 | 87.6 | 3.1 |
| Inventory | 6.82B | 7.48B | 7.99B | 8.35B | 8.71B | 8.96B | 9.67B | 9.43B | 22.69B |
| Days Inventory Outstanding | 214.29 | 238.66 | 243.58 | 250.72 | 259.57 | 275.24 | 279.39 | 260.68 | 640.89 |
| Other Current Assets | 210M | 363M | 299M | 958M | 1.35B | 870M | 471M | 13.71B | 208.17M |
| Total Non-Current Assets | 73.46B | 86.83B | 84.13B | 80.71B | 89.68B | 92.7B | 95.81B | 90.21B | 95.85B |
| Property, Plant & Equipment | 9.58B | 9.65B | 11.02B | 10.56B | 11.98B | 11.68B | 11.81B | 11.6B | 11.51B |
| Fixed Asset Turnover | 3.78x | 3.70x | 3.42x | 3.54x | 3.27x | 3.47x | 3.52x | 3.82x | 4.06x |
| Goodwill | 40.26B | 44.23B | 44.52B | 44.36B | 48.06B | 49.89B | 49.4B | 43.38B | 0 |
| Intangible Assets | 13.08B | 21.89B | 16.57B | 18.34B | 21.41B | 21.64B | 24.32B | 22.63B | 67.56B |
| Long-Term Investments | 6.14B | 6.17B | 5.99B | 2.67B | 2.91B | 3.22B | 3.26B | 3.26B | 0 |
| Other Non-Current Assets | 104M | 271M | 595M | 600M | 731M | 882M | 588M | 1.37B | 16.78B |
| Total Assets | 99.81B▲ 0% | 111.41B▲ 11.6% | 112.74B▲ 1.2% | 114.41B▲ 1.5% | 120.24B▲ 5.1% | 126.72B▲ 5.4% | 126.46B▼ 0.2% | 132.8B▲ 5.0% | 126.81B▼ 4.5% |
| Asset Turnover | 0.36x | 0.32x | 0.33x | 0.33x | 0.33x | 0.32x | 0.33x | 0.33x | 0.37x |
| Asset Growth % | -4.64% | 11.62% | 1.19% | 1.49% | 5.09% | 5.39% | -0.2% | 5.01% | -4.51% |
| Total Current Liabilities | 15.46B | 17.38B | 20.38B | 19.25B | 21.3B | 23.96B | 24.19B | 29.16B | 28.35B |
| Accounts Payable | 4.63B | 5.04B | 5.31B | 5.29B | 6.18B | 6.81B | 7.33B | 7.55B | 22.93B |
| Days Payables Outstanding | 145.62 | 160.91 | 161.89 | 158.95 | 184.06 | 209.29 | 211.81 | 208.72 | 647.56 |
| Short-Term Debt | 1.27B | 2.63B | 4.82B | 3B | 3.45B | 4.45B | 2.32B | 4.21B | 4.34B |
| Deferred Revenue (Current) | 0 | 0 | 0 | 252M | 319M | 264M | 0 | 0 | 0 |
| Other Current Liabilities | 6.45B | 6.98B | 7.66B | 9.75B | 10.61B | 11.86B | 11.57B | 15.13B | 64.08M |
| Current Ratio | 1.70x | 1.41x | 1.40x | 1.75x | 1.44x | 1.42x | 1.27x | 1.46x | 1.09x |
| Quick Ratio | 1.26x | 0.98x | 1.01x | 1.32x | 1.03x | 1.05x | 0.87x | 1.14x | 0.29x |
| Cash Conversion Cycle | 156.09 | 173.36 | 179.49 | 188.98 | 166.69 | 162.65 | 164.4 | 139.57 | -3.57 |
| Total Non-Current Liabilities | 26.11B | 35B | 33.25B | 31.91B | 29.92B | 27.61B | 27.92B | 25.78B | 26.74B |
| Long-Term Debt | 14.31B | 21.99B | 20.13B | 19.75B | 17.12B | 14.86B | 14.35B | 11.79B | 15.71B |
| Capital Lease Obligations | 20M | 18M | 987M | 931M | 1.84B | 1.9B | 1.75B | 1.65B | 1.47B |
| Deferred Tax Liabilities | 1.6B | 3.41B | 2.29B | 1.77B | 1.62B | 1.84B | 1.86B | 2.17B | 1.67B |
| Other Non-Current Liabilities | 10.18B | 9.58B | 9.84B | 9.47B | 9.34B | 9B | 9.96B | 10.18B | 7.9B |
| Total Liabilities | 41.57B | 52.37B | 53.63B | 51.16B | 51.21B | 51.57B | 52.11B | 54.94B | 55.1B |
| Total Debt | 15.6B | 24.64B | 25.93B | 23.68B | 22.41B | 21.21B | 18.7B | 17.91B | 21.79B |
| Net Debt | 5.29B | 17.71B | 16.19B | 9.76B | 12.32B | 8.48B | 9.99B | 10.46B | 14.13B |
| Debt / Equity | 0.27x | 0.42x | 0.44x | 0.37x | 0.32x | 0.28x | 0.25x | 0.23x | 0.30x |
| Debt / EBITDA | 1.64x | 2.75x | 2.47x | 1.33x | 1.95x | 1.60x | 1.64x | 1.65x | 2.28x |
| Net Debt / EBITDA | 0.56x | 1.98x | 1.54x | 0.55x | 1.07x | 0.64x | 0.88x | 0.97x | 1.48x |
| Interest Coverage | 17.85x | 10.07x | 6.00x | 32.99x | 21.69x | 27.03x | 13.57x | 11.96x | 17.51x |
| Total Equity | 58.24B▲ 0% | 59.03B▲ 1.4% | 59.11B▲ 0.1% | 63.25B▲ 7.0% | 69.03B▲ 9.1% | 75.15B▲ 8.9% | 74.35B▼ 1.1% | 77.86B▲ 4.7% | 71.71B▼ 7.9% |
| Equity Growth % | 0.89% | 1.37% | 0.12% | 7.01% | 9.14% | 8.87% | -1.06% | 4.71% | -7.9% |
| Book Value per Share | 23.17 | 23.67 | 23.65 | 25.23 | 27.56 | 30.02 | 29.59 | 31.11 | 29.38 |
| Total Shareholders' Equity | 58.07B | 58.88B | 58.93B | 63.11B | 68.68B | 74.78B | 74.04B | 77.51B | 71.38B |
| Common Stock | 2.51B | 2.5B | 2.51B | 2.52B | 2.53B | 2.52B | 2.53B | 2.53B | 71.38B |
| Retained Earnings | 52.86B | 53.11B | 51.78B | 60.15B | 63.01B | 66.73B | 67.5B | 0 | 0 |
| Treasury Stock | -14M | -153M | -9M | -705M | -939M | -706M | -1.18B | -840M | 0 |
| Accumulated OCI | 2.71B | 3.43B | 4.51B | 782M | 3.55B | 6.11B | 4.88B | 70.56B | 0 |
| Minority Interest | 169M | 159M | 174M | 146M | 350M | 368M | 313M | 350M | 334M |
SNY Cash Flow Statement
Sanofi (SNY) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 7.38B | 5.55B | 7.74B | 7.45B | 10.52B | 10.53B | 10.26B | 9.08B | 10.75B |
| Operating CF Margin % | 20.37% | 15.55% | 20.58% | 19.93% | 26.86% | 25.95% | 24.65% | 20.51% | 23.01% |
| Operating CF Growth % | -5.86% | -24.83% | 39.61% | -3.81% | 41.25% | 0.04% | -2.55% | -11.47% | 18.38% |
| Net Income | 8.43B | 4.31B | 1.86B | 12.31B | 6.22B | 8.37B | 5.4B | 5.5B | 7.81B |
| Depreciation & Amortization | 3.69B | 4.28B | 7.45B | 3.3B | 3.35B | 3.42B | 3.78B | 3.59B | 3.21B |
| Stock-Based Compensation | 263M | 284M | 252M | 0 | 244M | 245M | 0 | 0 | 0 |
| Deferred Taxes | -909M | -727M | -1.75B | -221M | -356M | -578M | -1.23B | -802M | 0 |
| Other Non-Cash Items | -3.98B | -1.03B | 355M | -7.62B | -349M | -225M | 1.55B | 1.42B | -2.07B |
| Working Capital Changes | 148M | -1.28B | -419M | -325M | 1.41B | -707M | 764M | -615M | 1.79B |
| Change in Receivables | -529M | -35M | -462M | -134M | 185M | -777M | -397M | -28M | -1.2B |
| Change in Inventory | -145M | -701M | -547M | -593M | -357M | -927M | -840M | -477M | -39M |
| Change in Payables | 577M | 270M | 169M | 86M | 451M | 452M | 402M | 789M | 398M |
| Cash from Investing | 639M | -12.87B | -1.06B | 3.59B | -7.3B | -2.08B | -6.2B | -4.41B | -2.35B |
| Capital Expenditures | -1.96B | -1.98B | -1.82B | -2.11B | -2.04B | -2.2B | -3.25B | -3.23B | -1.86B |
| CapEx % of Revenue | 5.4% | 5.54% | 4.83% | 5.66% | 5.22% | 5.43% | 7.82% | 7.3% | 3.98% |
| Acquisitions | -1.15B | -12.86B | -488M | 5.03B | -5.59B | -858M | 1.01B | -2.52B | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 3.91B | 2.1B | -94M | -113M | -68M | 1.47B | -3.87B | 1.35B | -492.42M |
| Cash from Financing | -7.9B | 3.93B | -4.19B | -6.49B | -7.06B | -5.82B | -8.05B | -5.76B | -8.21B |
| Debt Issued (Net) | -2.3B | 8.72B | -491M | -2.17B | -2.8B | -1.23B | -3.14B | -894M | 1.76B |
| Equity Issued (Net) | -1.84B | -924M | -9M | -822M | -196M | -497M | -398M | -115M | -4.66B |
| Dividends Paid | -3.71B | -3.77B | -3.83B | -3.94B | -4.01B | -4.17B | -4.45B | -4.7B | -4.58B |
| Share Repurchases | -2.16B | -1.1B | -9M | -822M | -382M | -497M | -593M | -302M | -4.83B |
| Other Financing | -15M | -91M | 141M | 441M | -48M | 77M | -63M | -50M | -726.37M |
| Net Change in Cash | 42M▲ 0% | -3.39B▼ 8171.4% | 2.5B▲ 173.8% | 4.49B▲ 79.4% | -3.82B▼ 185.0% | 2.64B▲ 169.1% | -4.03B▼ 252.6% | -1.27B▲ 68.5% | 216M▲ 117.0% |
| Free Cash Flow | 5.42B▲ 0% | 3.57B▼ 34.2% | 5.93B▲ 66.1% | 5.33B▼ 10.0% | 8.48B▲ 58.9% | 8.32B▼ 1.8% | 8.64B▲ 3.8% | 5.89B▼ 31.9% | 8.89B▲ 51.1% |
| FCF Margin % | 14.97% | 10.01% | 15.75% | 14.28% | 21.64% | 20.52% | 20.76% | 13.29% | 19.03% |
| FCF Growth % | -5.77% | -34.17% | 66.05% | -10% | 58.93% | -1.82% | 3.77% | -31.87% | 51.07% |
| FCF per Share | 2.16 | 1.43 | 2.37 | 2.13 | 3.38 | 3.32 | 3.44 | 2.35 | 3.64 |
| FCF Conversion (FCF/Net Income) | 0.88x | 1.29x | 2.81x | 0.61x | 1.69x | 1.26x | 1.90x | 1.63x | 1.38x |
| Interest Paid | 347M | 412M | 379M | 315M | 334M | 380M | 559M | 587M | 485M |
| Taxes Paid | 1.73B | 2.06B | 1.7B | 2.05B | 1.28B | 2.45B | 2.62B | 3.29B | 2.88B |
SNY Key Ratios
Sanofi (SNY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 8.12% | 14.52% | 7.34% | 4.66% | 20.09% | 9.41% | 11.61% | 7.22% | 7.31% | 10.45% |
| Return on Invested Capital (ROIC) | 7.44% | 6.72% | 5% | 3.01% | 14.27% | 7.9% | 9.24% | 6.22% | 6.3% | 5.46% |
| Gross Margin | 69.16% | 67.94% | 67.95% | 68.17% | 67.46% | 68.72% | 70.71% | 69.66% | 70.18% | 72.34% |
| Net Margin | 13.57% | 23.24% | 12.07% | 7.32% | 32.9% | 15.89% | 20.64% | 12.98% | 12.55% | 16.72% |
| Debt / Equity | 0.32x | 0.27x | 0.42x | 0.44x | 0.37x | 0.32x | 0.28x | 0.25x | 0.23x | 0.30x |
| Interest Coverage | 16.52x | 17.85x | 10.07x | 6.00x | 32.99x | 21.69x | 27.03x | 13.57x | 11.96x | 17.51x |
| FCF Conversion | 1.66x | 0.88x | 1.29x | 2.81x | 0.61x | 1.69x | 1.26x | 1.90x | 1.63x | 1.38x |
| Revenue Growth | -0.47% | 4.4% | -1.5% | 5.48% | -0.7% | 4.83% | 3.54% | 2.61% | 6.41% | 5.49% |
SNY Frequently Asked Questions
Sanofi (SNY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sanofi (SNY) reported $46.72B in revenue for fiscal year 2025. This represents a 773% increase from $5.35B in 1999.
Sanofi (SNY) grew revenue by 5.5% over the past year. This is steady growth.
Yes, Sanofi (SNY) is profitable, generating $7.81B in net income for fiscal year 2025 (16.7% net margin).
Dividend & Returns
Yes, Sanofi (SNY) pays a dividend with a yield of 5.08%. This makes it attractive for income-focused investors.
Sanofi (SNY) has a return on equity (ROE) of 10.4%. This is reasonable for most industries.
Sanofi (SNY) generated $8.28B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More SNY
Sanofi (SNY) financial analysis — history, returns, DCA and operating performance tools
Full SNY Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates